# Evaluation of AZD8154 Concentrations in Blood

> **NCT04480879** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** AZD8154 nebuliser
- **DRUG:** AZD8154 Monodose DPI presented in capsules
- **DRUG:** AZD8154 Placebo Monodose DPI presented in capsules

## Key facts

- **NCT ID:** NCT04480879
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-17
- **Primary completion:** 2020-09-02
- **Final completion:** 2020-09-02
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Need for evaluation of emerging pre-clinical toxicology findings
- **Last updated:** 2021-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480879, "Evaluation of AZD8154 Concentrations in Blood". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04480879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*